Drugs / BYON4413
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06359002 | Jun 2024 → Sep 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | Byondis B.V. | Active not recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-08 | Byondis B.V. | Poster presentation at AACR Annual Meeting 2024: BYON4413 byondis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BYON4413 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06359002 ↗ |
| Route | Intravenous | “BYON4413 will be administered by IV infusion.” NCT06359002 ↗ |